Novo Seeds launches a new neuro biotech as Alzheimer's R&D booms
Novo Holdings’ seed capital arm Novo Seeds is once again launching a new biotech, and this time it comes from the combination of two European startups.
The newco will take the efforts of Denmark’s Muna Therapeutics and Belgium’s K5 Therapeutics and fold them into one company, which will retain the Muna name. Novo Seeds is fronting the Series A with $73 million as the biotech looks to treat neurodegenerative diseases like Alzheimer’s, Parkinson’s and ALS.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.